LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 201–300 of 1,004
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
“An LNAantimiR to miR-122 in African green monkeys increased hepatic fatty acid oxidation and reduced plasma cholesterol and cholesterol synthesis.(133) Antagomirs of miR-33a and miR-33b in African green monkeys increased plasma HDL-cholesterol.”
BackgroundMicroRNAs in development and disease
Erson, A., & Petty, E. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01076.x · Cited by 228
“Chemically engineered antagomirs’ in mice (132) and locked nucleic acidmodified oligos in non-human primates (133) seem to be promising for efficient and specific silencing of miRNAs.”
BackgroundA Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies
Forterre, A., Komuro, H., Aminova, S., & Harada, M. (2020) · Cancers · doi:10.3390/cancers12071852 · Cited by 227
miRNA Therapeutics: A New Class of Drugs with Potential Therapeutic Applications in the Heart
Bernardo, B. C., Ooi, J. Y., Lin, R. C., & McMullen, J. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.107 · Cited by 226
Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy
Pezacki, J. P., Blake, J. A., Danielson, D. C., Kennedy, D. C., Lyn, R. K., & Singaravelu, R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.525 · Cited by 226
“Several studies have shown the liver-specific microRNA miR-122 is a key regulator of cholesterol biosynthesis as well as of HCV replication [93] [94] [95] [96] .”
BackgroundRole of microRNAs in obesity and obesity-related diseases
Iacomino, G., & Siani, A. (2017) · Genes & Nutrition · doi:10.1186/s12263-017-0577-z · Cited by 226
“Similarly, antisense inhibition of this miRNA in chimpanzee provokes a plasma cholesterol reduction supporting its key role in maintaining liver homeostasis [126].”
BackgroundMicroRNAs are associated with human embryo implantation defects
Revel, A., Achache, H., Stevens, J., Smith, Y., & Reich, R. (2011) · Human Reproduction · doi:10.1093/humrep/der255 · Cited by 224
“Because therapeutic antagonism of miRNAs has been successful in non-human primates (Elmen et al., 2008), the RIF-associated miRNAs should be evaluated as new candidates for the diagnosis and treatment of embryo implantation failures.”
BackgroundMarquez, R. T., Bandyopadhyay, S., Wendlandt, E. B., Keck, K., Hoffer, B. A., Icardi, M. S., Christensen, R. N., Schmidt, W. N., & McCaffrey, A. P. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.126 · Cited by 223
“Although our data suggest that inhibition of miR-122 correlates with fibrosis, long term miR-122 inhibition in African green monkeys did not result in liver pathology, suggesting that downregulation of miR-122 does not cause liver fibrosis.(19) Figure 4 miR-21 directly targets the 30UTR of SMAD7.”
BackgroundDiagnostic, functional, and therapeutic roles of microRNA in allergic diseases
Lu, T. X., & Rothenberg, M. E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.039 · Cited by 222
MicroRNAs and potential target interactions in psoriasis
Zibert, J. R., Løvendorf, M. B., Litman, T., Olsen, J., Kaczkowski, B., & Skov, L. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.03.004 · Cited by 221
“been suggested that knowledge of deregulation at the posttranscriptional level could lead to a direct antisense targeting of miRNAs [46].”
Götte, M., Mohr, C., Koo, C.-Y., Stock, C., Vaske, A.-K., Viola, M., Ibrahim, S. A., Peddibhotla, S., Teng, Y. H.-F., Low, J.-Y., et al. (2010) · Oncogene · doi:10.1038/onc.2010.386 · Cited by 220
“…future application of locked nucleic acid-derivatives of pre-miR-145 in pre-clinical and clinical settings may represent less of a challenge than expected, as Elmén et al. (2008) demonstrated safe and efficient in vivo effects of locked nucleic acid-antimiR treatment in a nonhuman primate model.”
BackgroundVirus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer
McGivern, D. R., & Lemon, S. M. (2011) · Oncogene · doi:10.1038/onc.2010.594 · Cited by 219
“It is developmentally regulated and expressed almost exclusively in liver, controlling the expression of numerous hepatocyte-specific genes and promoting hepatocellular differentiation (Chang et al 2004, Elmen et al 2008, Krutzfeldt et al 2005).”
BackgroundmiR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
Park, J.-K., Kogure, T., Nuovo, G. J., Jiang, J., He, L., Kim, J. H., Phelps, M. A., Papenfuss, T. L., Croce, C. M., Patel, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1144 · Cited by 219
Control of Cholesterol Metabolism and Plasma High-Density Lipoprotein Levels by microRNA-144
Ramírez, C. M., Rotllan, N., Vlassov, A. V., Dávalos, A., Li, M., Goedeke, L., Aranda, J. F., Cirera-Salinas, D., Araldi, E., Salerno, A., et al. (2013) · Circulation Research · doi:10.1161/circresaha.112.300626 · Cited by 233
“Interestingly some of the miRNAs induced by T090, including miR-370 and miR-122, were previously identified as important regulators of lipid metabolism.(15,16,18,28) To determine the potential candidates involved in regulating cholesterol metabolism, we analyzed the predicted target genes using a combination of bioinf…”
MethodLong-term, efficient inhibition of microRNA function in mice using rAAV vectors
Xie, J., Ameres, S. L., Friedline, R., Hung, J.-H., Zhang, Y., Xie, Q., Zhong, L., Su, Q., He, R., Li, M., et al. (2012) · Nature Methods · doi:10.1038/nmeth.1903 · Cited by 217
Corsten, M. F., Papageorgiou, A., Verhesen, W., Carai, P., Lindow, M., Obad, S., Summer, G., Coort, S. L. M., Hazebroek, M., van Leeuwen, R., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.267443 · Cited by 216
Self-citationEfficient inhibition of miR-155 function in vivo by peptide nucleic acids
Fabani, M. M., Abreu-Goodger, C., Williams, D., Lyons, P. A., Torres, A. G., Smith, K. G. C., Enright, A. J., Gait, M. J., & Vigorito, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq160 · Cited by 214
“ONs of different chemistries such as LNA/DNA mixmers, MOEs and ‘antagomirs’ have proven successful for blocking miRNA expression in vivo, as exemplified by targeting of miR-122 and miR-155 (11,12,14,44,45).”
BackgroundRegulation of cholesterol homeostasis
Goedeke, L., & Fernández-Hernando, C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0857-5 · Cited by 213
“’ Additionally, the production of the mature forms can also be disrupted at the processing level [24, 25, 157, 179].”
BackgroundJimenez-Mateos, E. M., Bray, I., Sanz-Rodriguez, A., Engel, T., McKiernan, R. C., Mouri, G., Tanaka, K., Sano, T., Saugstad, J. A., Simon, R. P., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.036 · Cited by 211
Kim, M., Kim, C., Choi, Y. S., Kim, M., Park, C., & Suh, Y. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.03.014 · Cited by 211
Oncogenic Role of miR-483-3p at the IGF2/483 Locus
Veronese, A., Lupini, L., Consiglio, J., Visone, R., Ferracin, M., Fornari, F., Zanesi, N., Alder, H., D'Elia, G., Gramantieri, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4456 · Cited by 210
“anti-miRNAs in animal models, including African green monkeys, suggests the potential application of AMOs in anticancer therapy as well (35, 36).”
BackgroundDownregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity
Zhou, B., Li, C., Qi, W., Zhang, Y., Zhang, F., Wu, J. X., Hu, Y. N., Wu, D. M., Liu, Y., Yan, T. T., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2539-8 · Cited by 209
“The efficacy and safety of LNA antisense oligonucleotides in inhibiting miRNA targets have been shown in mouse and non-human primate models [38, 39].”
BackgroundMicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
Shea, A., Harish, V., Afzal, Z., Chijioke, J., Kedir, H., Dusmatova, S., Roy, A., Ramalinga, M., Harris, B., Blancato, J., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.775 · Cited by 209
“This was accompanied by effective lowering of plasma cholesterol levels and no evidence of toxicity or histopathological changes [119].”
BackgroundMicroRNAs as potential cancer therapeutics
Trang, P., Weidhaas, J. B., & Slack, F. J. (2008) · Oncogene · doi:10.1038/onc.2009.353 · Cited by 208
“As an alternative to 20-hydroxyl-modified AMOs, lock nucleic acid (LNA)-based oligonucleotides (LNA-antimiR) have been shown to be more stable and less toxic in inhibiting endogenous miRNAs in vivo (Vester and Wengel, 2004; Elmen et al., 2008).”
BackgroundMethodMiR-122 in hepatic function and liver diseases
Hu, J., Xu, Y., Hao, J., Wang, S., Li, C., & Meng, S. (2012) · Protein & Cell · doi:10.1007/s13238-012-2036-3 · Cited by 208
MicroRNA Therapeutics in Cancer: Current Advances and Challenges
Reda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., & Cherradi, N. (2021) · Cancers · doi:10.3390/cancers13112680 · Cited by 206
Ahmad, A., Aboukameel, A., Kong, D., Wang, Z., Sethi, S., Chen, W., Sarkar, F. H., & Raz, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0965 · Cited by 205
Role of microRNAs in obesity and the metabolic syndrome
Heneghan, H. M., Miller, N., & Kerin, M. J. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00659.x · Cited by 203
“miR-122, using locked nucleic acid (LNA) modified DNA oligonucleotides (LNA-anti-miRs), resulted in effective silencing thus inhibiting HCV replication in HuH-7 cells harbouring the HCV-N replicon NNeo/C-5B (42).”
Sequence-non-specific effects of RNA interference triggers and microRNA regulators
Olejniczak, M., Galka, P., & Krzyzosiak, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp829 · Cited by 202
“These singlestranded antisense reagents that inhibit the RISC-bound miRNAs (45) differ in their length ranging from 16 nt (186) to 31 nt (183,187).”
BackgroundZhang, W. C., Chin, T. M., Yang, H., Nga, M. E., Lunny, D. P., Lim, E. K. H., Sun, L. L., Pang, Y. H., Leow, Y. N., Malusay, S. R. Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11702 · Cited by 202
“This strategy has been experimentally tested in mice and non-human primates for the treatment of several diseases 43 , and more recently, it has been applied in clinical trials for the treatment of hepatitis C 15 .”
Potent inhibition of microRNA in vivo without degradation
Davis, S., Propp, S., Freier, S. M., Jones, L. E., Serra, M. J., Kinberger, G., Bhat, B., Swayze, E. E., Bennett, C. F., & Esau, C. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn904 · Cited by 200
“However, inhibition of miRNA activity, measured by modulation of miRNA target genes, without degradation of the miRNA has recently been reported (10).”
BackgroundThe Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market
Titze-de-Almeida, R., David, C., & Titze-de-Almeida, S. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2134-2 · Cited by 200
Gao, W., He, H.-W., Wang, Z.-M., Zhao, H., Lian, X.-Q., Wang, Y.-S., Zhu, J., Yan, J.-J., Zhang, D.-G., Yang, Z.-J., et al. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-55 · Cited by 198
“It has been shown that miR-122 and miR-370 are over-expressed in the livers of hyperlipidemia animals [7,9,22].”
microRNA‐122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma
Burchard, J., Zhang, C., Liu, A. M., Poon, R. T. P., Lee, N. P. Y., Wong, K., Sham, P. C., Lam, B. Y., Ferguson, M. D., Tokiwa, G., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.58 · Cited by 195
“…each tissue type and extend literature reports of the association of miR-122-expression levels with lipid metabolism (Jopling et al, 2005; Esau et al, 2006; Elmén et al, 2008a, b; Coulouarn et al, 2009) and suppressing the metastatic properties of HCC (Tsai et al, 2008; Coulouarn et al, 2009).”
BackgroundMicroRNA therapeutics in cardiovascular medicine
Thum, T. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100191 · Cited by 193
“MiR-122 modulation in vitro and in vivo let to alterations of many genes implicated in liver metabolism, fatty acid synthesis and oxidation (Elmen et al, 2008a; Esau et al, 2006; Krutzfeldt et al, 2005).”
Wang, W.-T., Zhao, Y.-N., Han, B.-W., Hong, S.-J., & Chen, Y.-Q. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2415 · Cited by 193
“miRNAs may thus be attractive candidates for novel diagnostic markers and therapeutic interventions in endometriosis (15, 16).”
BackgroundRegulation of metabolism by long, non-coding RNAs
Kornfeld, J.-W., & Brüning, J. C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00057 · Cited by 193
Worm, J., Stenvang, J., Petri, A., Frederiksen, K. S., Obad, S., Elmén, J., Hedtjärn, M., Straarup, E. M., Hansen, J. B., & Kauppinen, S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp577 · Cited by 192
“We have recently reported on effective miRNA silencing using complementary LNA-antimiR oligonucleotides in combination with transcriptome analysis as a useful approach to dissect the biological roles of individual miRNAs in vitro and in vivo (20,21).”
Self-citationMicroRNAs and lipid metabolism
Aryal, B., Singh, A. K., Rotllan, N., Price, N., & Fernández-Hernando, C. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000420 · Cited by 191
miRNAs as Modulators of Angiogenesis
Landskroner-Eiger, S., Moneke, I., & Sessa, W. C. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006643 · Cited by 190
“As an alternative to 20-hydroxyl-modified AMOs, lock nucleic acid (LNA)–based oligonucleotides (LNA-antimiRs) have been shown to be more stable and less toxic in inhibiting endogenous miRNAs in vivo (Vester and Wengel 2004; Elmen et al. 2008).”
The role of microRNAs in normal and malignant hematopoiesis
Vasilatou, D., Papageorgiou, S., Pappa, V., Papageorgiou, E., & Dervenoulas, J. (2010) · European Journal of Haematology · doi:10.1111/j.1600-0609.2009.01348.x · Cited by 189
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth
Munir, M. T., Kay, M. K., Kang, M. H., Rahman, M. M., Al-Harrasi, A., Choudhury, M., Moustaid-Moussa, N., Hussain, F., & Rahman, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126526 · Cited by 188
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
Meta-regulation: microRNA regulation of glucose and lipid metabolism
Lynn, F. C. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.05.007 · Cited by 187
MicroRNA-mediated control of macrophages and its implications for cancer
Squadrito, M. L., Etzrodt, M., De Palma, M., & Pittet, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.003 · Cited by 187
“Other examples of miRNA delivery [74] or silencing [75,76] in mice and primates have been reported, and serve as proof-of-principle that miRNA-based therapies may become available to human patients in the near future.”
On the Importance of Host MicroRNAs During Viral Infection
Girardi, E., López, P., & Pfeffer, S. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00439 · Cited by 187
“Indeed, conservative estimates indicate that at least 60% of the human coding genome might be regulated by miRNAs (Friedman et al., 2009).”
Post-SELEX optimization of aptamers
Gao, S., Zheng, X., Jiao, B., & Wang, L. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9556-2 · Cited by 185
“The first model LNA that includes an LNA-modified oligonucleotide has reached clinical trials, with SPC 3649 (miravirsen) in phase II and SPC 4955 in phase I clinical studies [19, 20].”
BackgroundThe Role of Metformin in the Management of NAFLD
Mazza, A., Fruci, B., Garinis, G. A., Giuliano, S., Malaguarnera, R., & Belfiore, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/716404 · Cited by 184
“Particularly, both in monkeys [108] and in mice [107], antagomir against miRNA-122 resulted in a reduction of hepatic steatosis.”
BackgroundMetastamirs: a stepping stone towards improved cancer management
White, N. M. A., Fatoohi, E., Metias, M., Jung, K., Stephan, C., & Yousef, G. M. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.173 · Cited by 184
Differential expression of microRNAs in mouse liver under aberrant energy metabolic status
Li, S., Chen, X., Zhang, H., Liang, X., Xiang, Y., Yu, C., Zen, K., Li, Y., & Zhang, C.-Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800509-jlr200 · Cited by 184
miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling
Yang, S., Banerjee, S., Freitas, A. D., Cui, H., Xie, N., Abraham, E., & Liu, G. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00316.2011 · Cited by 183
A Direct Comparison of Anti-microRNA Oligonucleotide Potency
Lennox, K. A., & Behlke, M. A. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0156-0 · Cited by 182
“An examination of “DNA/LNA PS”-modified miR21 AMOs with lengths varying between 18 and 22nts did not show any significant differences in potency (data not shown), and modified compounds of this general design as short as 15nts have been used with success (40,50).”
MethodWitwer, K. W., Sisk, J. M., Gama, L., & Clements, J. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902712 · Cited by 181
“With an increasing number of innate immune system components showing evidence of miRNA targeting, the demonstrated potential of miRNA-based therapeutics (42, 69) provides a promising new possibility for modulation of the body’s first line of defense against viral infections.”
BackgroundMicroRNA regulation in angiogenesis
Caporali, A., & Emanueli, C. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.06.006 · Cited by 179
“Although both the antagomiR and LNA-modified oligos can effectively target a miRNA, the LNA-modified chemistries require lower doses based on their higher binding affinity (Elmen et al., 2008).”
Merkel cell polyomavirus encodes a microRNA with the ability to autoregulate viral gene expression
Seo, G. J., Chen, C. J., & Sullivan, C. S. (2009) · Virology · doi:10.1016/j.virol.2008.11.001 · Cited by 177
“Thus, combined with the recent successes in rationally-designed antimiRNA inhibitors (Elmen et al., 2008; Krutzfeldt et al., 2005), these”
BackgroundTherapeutic MicroRNA Strategies in Human Cancer
Li, C., Feng, Y., Coukos, G., & Zhang, L. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9145-9 · Cited by 177
“ribose moiety is chemically locked in a RNA-mimicking N-type (C3′-endo) conformation by the introduction of an extra 2′-O, 4′-C methylene bridge (77).”
BackgroundUeda, R., Kohanbash, G., Sasaki, K., Fujita, M., Zhu, X., Kastenhuber, E. R., McDonald, H. A., Potter, D. M., Hamilton, R. L., Lotze, M. T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811817106 · Cited by 176
“Recent studies have developed an attractive vehicle for in vivo miR-targeting with the use of antisense ‘‘antagomir’’ oligonucleotides (13).”
BackgroundPatel, V., & Noureddine, L. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e328354e559 · Cited by 176
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
“Such molecules have been shown to potently and safely inhibit both mRNA and miRNA targets in mouse [30] and non-human primate [31,32] models, and several different LNA drugs are currently in clinical trials against cancer and infectious diseases.”
BackgroundSelf-citationTargeting MicroRNAs in Cancer Gene Therapy
Ji, W., Sun, B., & Su, C. (2017) · Genes · doi:10.3390/genes8010021 · Cited by 174
microRNA: Emerging therapeutic targets in acute ischemic diseases
Fasanaro, P., Greco, S., Ivan, M., Capogrossi, M. C., & Martelli, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.003 · Cited by 174
MicroRNAs in adipose tissue: their role in adipogenesis and obesity
Hilton, C., Neville, M. J., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.59 · Cited by 174
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S.-H., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 173
MicroRNAs – micro in size but macro in function
Singh, S. K., Pal Bhadra, M., Girschick, H. J., & Bhadra, U. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06624.x · Cited by 172
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Functions of MicroRNAs in Cardiovascular Biology and Disease
Hata, A. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183737 · Cited by 171
Regulation of hepatitis C virus by microRNA-122
Jopling, C. L. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361220 · Cited by 174
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model
Callegari, E., Elamin, B. K., Giannone, F., Milazzo, M., Altavilla, G., Fornari, F., Giacomelli, L., D'Abundo, L., Ferracin, M., Bassi, C., et al. (2012) · Hepatology · doi:10.1002/hep.25747 · Cited by 170
“21,22 To support the idea that the up-regulation of miR-221 was important for promoting and maintaining liver tumors as well as investigating the potential antitumor activity of anti-miR-221, we sought to inhibit the endogenous miR-221 through in vivo delivery of anti-miR-221 AMOs.”
MicroRNAs and cardiovascular diseases
Ono, K., Kuwabara, Y., & Han, J. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08090.x · Cited by 169
High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
Leivonen, S.-K., Sahlberg, K. K., Mäkelä, R., Due, E. U., Kallioniemi, O., Børresen-Dale, A.-L., & Perälä, M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.10.001 · Cited by 169
Circulating microRNAs as Biomarkers, Therapeutic Targets, and Signaling Molecules
Ajit, S. K. (2012) · Sensors · doi:10.3390/s120303359 · Cited by 168
“miRNA inhibitors termed miRNA sponges [44], antagomirs [45], locked-nucleic-acid-modified oligonucleotides [46],”
BackgroundMicroRNAs in fibrosis: opportunities and challenges
O’Reilly, S. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0929-x · Cited by 165
“LNA-modified antagomirs were first used in vivo in non-human primates to target the liver miRNA-122 and resulted in a sustained and long-lasting decrease in cholesterol [54].”
BackgroundAntisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“miRNA function with ASOs has now been successfully shown in vitro and in vivo [45–48], and holds great therapeutic promise as the role of miRNAs in neurodegenerative diseases continues to develop [49].”
BackgroundNg, R., Song, G., Roll, G. R., Frandsen, N. M., & Willenbring, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci46039 · Cited by 164
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches
Callegari, E., Gramantieri, L., Domenicali, M., D'Abundo, L., Sabbioni, S., & Negrini, M. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.136 · Cited by 163
“The safety of this silencing approach was established in nonhuman primates, where no evidence of liver toxicity was detected.(163) On the basis of these promising results, many studies of miRNA inhibition were subsequently performed.”
BackgroundEmerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell
Sotiropoulou, G., Pampalakis, G., Lianidou, E., & Mourelatos, Z. (2009) · RNA · doi:10.1261/rna.1534709 · Cited by 157
“Further, LNAs were used to target miR-122 in African green monkeys and in mice, indicating that they have the potential to be used in humans (Elmén et al. 2008).”
MethodMiR-146a/b: a family with shared seeds and different roots
Paterson, M. R., & Kriegel, A. J. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00133.2016 · Cited by 162
“Anti-sense technologies utilize synthetic oligonucleotide sequences with complementarity to the mature miRNA with special chemical modifications that increases overall stability of the knock-down effect, and this can be successfully administered in vivo to knock down a specific miRNA (22, 25, 26, 47, 48).”
BackgroundHackl, M., Heilmeier, U., Weilner, S., & Grillari, J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.015 · Cited by 179
MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis
Kadera, B. E., Li, L., Toste, P. A., Wu, N., Adams, C., Dawson, D. W., & Donahue, T. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071978 · Cited by 147
“Systemically administered LNA antag-omiRs to miR-122 in nonhuman primates successfully reduced plasma cholesterol [47], and HCV viremia and associated liver changes [48].”
BackgroundTargeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality
Sun, Y., Varambally, S., Maher, C. A., Cao, Q., Chockley, P., Toubai, T., Malter, C., Nieves, E., Tawara, I., Wang, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325647 · Cited by 146
MicroRNAs: Opening a New Vein in Angiogenesis Research
Fish, J. E., & Srivastava, D. (2009) · Science Signaling · doi:10.1126/scisignal.252pe1 · Cited by 160
Dickinson, B. A., Semus, H. M., Montgomery, R. L., Stack, C., Latimer, P. A., Lewton, S. M., Lynch, J. M., Hullinger, T. G., Seto, A. G., & van Rooij, E. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft018 · Cited by 160
“Additionally, oligonucleotides designed to bind and sequester miRNAs have been shown to inhibit miRNA function pharmacologically in animals.(6) Recent phase II clinical data using miR-122 as a target for the treatment of hepatitis C virus (HCV) infection provide proof of concept for miRNA targeting in humans for thera…”
BackgroundSilencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro.
Abouheif, M., Nakasa, T., Shibuya, H., Niimoto, T., Kongcharoensombat, W., & Ochi, M. (2010) · Rheumatology · doi:10.1093/rheumatology/keq247 · Cited by 160
MicroRNAs: critical mediators of differentiation, development and disease
Friedman, J., & Jones, P. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12794 · Cited by 159
The Role of MicroRNAs in Cholesterol Efflux and Hepatic Lipid Metabolism
Moore, K. J., Rayner, K. J., Suárez, Y., & Fernández-Hernando, C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-081810-160756 · Cited by 151
“The promising results from mouse studies prompted the use of LNA-antagomirs directed against miR-122 to be test in non-human primates (18, 52).”
Bandyopadhyay, S., Friedman, R. C., Marquez, R. T., Keck, K., Kong, B., Icardi, M. S., Brown, K. E., Burge, C. B., Schmidt, W. N., Wang, Y., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir186 · Cited by 162
“Of note, inhibition of miR-122 in primates has been shown to be safe [45], and clinical trials are currently underway to determine whether modulation of miR-122 levels in humans inhibits HCV.”
Oncogenic effects of miR-10b in glioblastoma stem cells
Guessous, F., Alvarado-Velez, M., Marcinkiewicz, L., Zhang, Y., Kim, J., Heister, S., Kefas, B., Godlewski, J., Schiff, D., Purow, B., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1047-0 · Cited by 158
microRNAs and muscle disorders
Chen, J.-F., Callis, T. E., & Wang, D.-Z. (2009) · Journal of Cell Science · doi:10.1242/jcs.041723 · Cited by 158
“Recently, using the same principle, locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) was demonstrated to effectively antagonize miRNAs in non-human primates (Elmen et al., 2008).”
BackgroundMicroRNAs and Their Role in Progressive Kidney Diseases
Kato, M., Arce, L., & Natarajan, R. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00520109 · Cited by 158
Antisense Drug Discovery and Development
Yamamoto, T., Nakatani, M., Narukawa, K., & Obika, S. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.2 · Cited by 158
Aigner, A. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0716-0 · Cited by 152
“liver [80].”
microRNAs and cholesterol metabolism
Moore, K. J., Rayner, K. J., Suárez, Y., & Fernández-Hernando, C. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.08.008 · Cited by 151
“Microarray analyses of the livers of miR-122 ASO treated mice showed upregulation in the mRNAs of up to 400 genes, of which approximately 70% had at least one 6-nt seed match for miR-122 in their 3′UTR [62,63,65].”
BackgroundMethodMicroRNA Expression Abnormalities in Limited Cutaneous Scleroderma and Diffuse Cutaneous Scleroderma
Zhu, H., Li, Y., Qu, S., Luo, H., Zhou, Y., Wang, Y., Zhao, H., You, Y., Xiao, X., & Zuo, X. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9647-y · Cited by 168
“MiRNAbased therapeutic approaches in animal studies of other diseases have been encouraging, since toxic effects were not observed [21–23].”
MicroRNAs and cancer epigenetics: a macrorevolution
Dávalos, V., & Esteller, M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333dcbb · Cited by 155
Obesity and genetics regulate microRNAs in islets, liver, and adipose of diabetic mice
Zhao, E., Keller, M. P., Rabaglia, M. E., Oler, A. T., Stapleton, D. S., Schueler, K. L., Neto, E. C., Moon, J. Y., Wang, P., Wang, I.-M., et al. (2009) · Mammalian Genome · doi:10.1007/s00335-009-9217-2 · Cited by 148
“Similar findings have been reported in primate liver (Elmen et al. 2008), suggesting that miR-122a plays an important role in lipid metabolism across multiple species.”
ResultLNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas
Zhang, Y., Roccaro, A. M., Rombaoa, C., Flores, L., Obad, S., Fernandes, S. M., Sacco, A., Liu, Y., Ngo, H., Quang, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410647 · Cited by 150
Self-citationMiR‐26 controls LXR‐dependent cholesterol efflux by targeting ABCA1 and ARL7
Sun, D., Zhang, J., Xie, J., Wei, W., Chen, M., & Zhao, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.068 · Cited by 136
“We detected the reported miRNAs such as miR-33 [25–28], miR-146a [31], miR-122 [32,33], miR-370 [34], miR-378 [35], miR-27 [36] and miR-125a-5p [37], which either participated in the regulation of cholesterol metabolism, or related to the atherosclerosis.”
MethodNoncoding RNAs in cancer and cancer stem cells
Huang, T., Alvarez, A. A., Hu, B., & Cheng, S. (2013) · 癌症:英文版 · doi:10.5732/cjc.013.10170 · Cited by 147
“Based on the knowledge that miRNAs control their targets through base pair complementarity, antisense oligonucleotides (ASOs) have been developed to inhibit miRNA function.”
BackgroundRole of MicroRNAs in Cardiac Remodeling and Heart Failure
Topkara, V. K., & Mann, D. L. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6289-5 · Cited by 145
“gov identifier: NCT01200420) [47, 48].”
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier
Lennox, K. A., Owczarzy, R., Thomas, D. M., Walder, J. A., & Behlke, M. A. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.46 · Cited by 158
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.